A socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of international conventions; exhibitions; and business, public, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 160 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 75 countries worldwide.

The Roscongress Foundation has Telegram channels in Russian (t.me/Roscongress), English (t.me/RoscongressDirect), and Spanish (t.me/RoscongressEsp). Official website and Information and Analytical System of the Roscongress Foundation: roscongress.org.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Socially Responsible Business: the Pharma Industry in the Patients’ Interests
2 June 2021

Under the pressure of overwhelming circumstances, constituted by the COVID-19 pandemic and subsequent isolation, a number of industries had to expedite their transition to new operating environment. Healthcare was no exception and transformation of the industry to principles of patient-focusing began in next to no time. The pharma business, solving the problems of quick and continuous access to drug treatment, has put patients’ interests as the foundation for adaptation of its business models. In the course of carrying out the project to ensure remote delivery of drugs, pharma companies have spared no effort to ensure continuity of the new service. An infrastructure was created that needed to comply with requirements established by the government of the Russian Federation to counter dishonest suppliers; drug labelling was introduced; special facilities were equipped for storage of reserved drugs, and courier departments were created. Right now, there is talk of switching to a system of drug reimbursement. Regardless of the reimbursement model chosen, it is already clear that the social role that the pharma business plays will increase, which will take it from the service provider category to the rank of a coequal partner. And in the event of successful cooperation between the government and business, there is an opportunity for carrying out new and even larger joint projects. How specifically can the pharma business help in implementing government social projects involving drug supply? Is the industry ready for increased social responsibility? Patient focus is one of the key trends in the medical industry in recent years. How can pharma companies promote its integration in the healthcare system? What patient support programmes have become noticeable on the global market? The essence of the pharma business is in providing socially significant services by supplying the population with drugs. Where is the line between business and charity? The COVID-19 epidemic demonstrated that given reduction of the regulatory load, national pharma companies are capable of fully satisfying the demand of the population for drug access. What is the potential today for statutory accommodation of negotiations processes between the regulators and business?

Started at
Conference hall
Pavilion G, conference hall G3
Analytics on the topic